p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours

Marie Lise Jaffrain-Rea, E. Ferretti, E. Toniato, K. Cannita, A. Santoro, D. Di Stefano, E. Ricevuto, M. Maroder, G. Tamburrano, G. Cantore, A. Gulino, S. Martinotti

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

OBJECTIVE: The p16 gene, which encodes a physiological inhibitor of the cyclin D-CDK4 complex, is now considered as an important tumour-suppressor gene in a variety of tumours. A marked reduction of its expression has been reported to occur without significant genetic alterations in human pituitary adenomas, although rare point mutations of uncertain functional significance have been described. On the other hand, p16 gene silencing due to hypermethylation has been reported in several human primary tumours. The aim of this study was to further investigate the pathogenetic events leading to p16 gene inactivation in pituitary tumours. DESIGN: To screen a european series of human pituitary tumours for p16 gene alterations and possible gene hypermethylation. PATIENTS: A representative series of 31 human pituitary tumours - 30 macroadenomas, including a MEN-1 non-secreting pituitary adenoma and a non-MEN-1 familial giant GH-secreting adenoma, and one FSH-secreting pituitary carcinoma was studied. METHODS: Polymerase chain reaction/single strand conformation polymorphism (PCR-SSCP) analysis was used to screen for p16 gene alterations in all cases. Direct sequencing of PCR-products was obtained by the di-deoxynucleotide method where suspected abnormalities of the PCR-SSCP analysis were observed. In 24 samples, a methylation-specific PCR assay (MSP-PCR) was used to determine p16 gene methylation status. RESULTS: Two sporadic cases of pituitary adenomas had a similar single A to G base substitution leading to an heterozygous Ala140Thr p16 polymorphism, which has not previously been described in such tumours, but is known to be functionally silent. No other p16 abnormality could be suspected from PCR- SSCP analysis in this series. In contrast, the presence of methylated- specific PCR products was observed in 20/24 cases (83.3%). CONCLUSIONS: This study confirms that p16 gene mutations are not involved in the pathogenesis of human pituitary tumours, although polymorphisms can be demonstrated, depending on the population considered. In contrast, the high incidence of hypermethylation of the p16 gene suggests that such an alteration occurs early in pituitary tumours, and may play a role in pituitary tumorigenesis.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalClinical Endocrinology
Volume51
Issue number3
DOIs
Publication statusPublished - 1999

Fingerprint

p16 Genes
Pituitary Neoplasms
Methylation
Genes
Polymerase Chain Reaction
Gene Silencing
Cyclin D
Multiple Endocrine Neoplasia Type 1
Single-Stranded Conformational Polymorphism
Neoplasms
Tumor Suppressor Genes
Point Mutation
Adenoma
Carcinogenesis
Mutation
Incidence

ASJC Scopus subject areas

  • Endocrinology

Cite this

Jaffrain-Rea, M. L., Ferretti, E., Toniato, E., Cannita, K., Santoro, A., Di Stefano, D., ... Martinotti, S. (1999). p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clinical Endocrinology, 51(3), 317-325. https://doi.org/10.1046/j.1365-2265.1999.00774.x

p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. / Jaffrain-Rea, Marie Lise; Ferretti, E.; Toniato, E.; Cannita, K.; Santoro, A.; Di Stefano, D.; Ricevuto, E.; Maroder, M.; Tamburrano, G.; Cantore, G.; Gulino, A.; Martinotti, S.

In: Clinical Endocrinology, Vol. 51, No. 3, 1999, p. 317-325.

Research output: Contribution to journalArticle

Jaffrain-Rea, ML, Ferretti, E, Toniato, E, Cannita, K, Santoro, A, Di Stefano, D, Ricevuto, E, Maroder, M, Tamburrano, G, Cantore, G, Gulino, A & Martinotti, S 1999, 'p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours', Clinical Endocrinology, vol. 51, no. 3, pp. 317-325. https://doi.org/10.1046/j.1365-2265.1999.00774.x
Jaffrain-Rea ML, Ferretti E, Toniato E, Cannita K, Santoro A, Di Stefano D et al. p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clinical Endocrinology. 1999;51(3):317-325. https://doi.org/10.1046/j.1365-2265.1999.00774.x
Jaffrain-Rea, Marie Lise ; Ferretti, E. ; Toniato, E. ; Cannita, K. ; Santoro, A. ; Di Stefano, D. ; Ricevuto, E. ; Maroder, M. ; Tamburrano, G. ; Cantore, G. ; Gulino, A. ; Martinotti, S. / p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. In: Clinical Endocrinology. 1999 ; Vol. 51, No. 3. pp. 317-325.
@article{0a50620fbfed45d0a7e56d2dd58fade6,
title = "p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours",
abstract = "OBJECTIVE: The p16 gene, which encodes a physiological inhibitor of the cyclin D-CDK4 complex, is now considered as an important tumour-suppressor gene in a variety of tumours. A marked reduction of its expression has been reported to occur without significant genetic alterations in human pituitary adenomas, although rare point mutations of uncertain functional significance have been described. On the other hand, p16 gene silencing due to hypermethylation has been reported in several human primary tumours. The aim of this study was to further investigate the pathogenetic events leading to p16 gene inactivation in pituitary tumours. DESIGN: To screen a european series of human pituitary tumours for p16 gene alterations and possible gene hypermethylation. PATIENTS: A representative series of 31 human pituitary tumours - 30 macroadenomas, including a MEN-1 non-secreting pituitary adenoma and a non-MEN-1 familial giant GH-secreting adenoma, and one FSH-secreting pituitary carcinoma was studied. METHODS: Polymerase chain reaction/single strand conformation polymorphism (PCR-SSCP) analysis was used to screen for p16 gene alterations in all cases. Direct sequencing of PCR-products was obtained by the di-deoxynucleotide method where suspected abnormalities of the PCR-SSCP analysis were observed. In 24 samples, a methylation-specific PCR assay (MSP-PCR) was used to determine p16 gene methylation status. RESULTS: Two sporadic cases of pituitary adenomas had a similar single A to G base substitution leading to an heterozygous Ala140Thr p16 polymorphism, which has not previously been described in such tumours, but is known to be functionally silent. No other p16 abnormality could be suspected from PCR- SSCP analysis in this series. In contrast, the presence of methylated- specific PCR products was observed in 20/24 cases (83.3{\%}). CONCLUSIONS: This study confirms that p16 gene mutations are not involved in the pathogenesis of human pituitary tumours, although polymorphisms can be demonstrated, depending on the population considered. In contrast, the high incidence of hypermethylation of the p16 gene suggests that such an alteration occurs early in pituitary tumours, and may play a role in pituitary tumorigenesis.",
author = "Jaffrain-Rea, {Marie Lise} and E. Ferretti and E. Toniato and K. Cannita and A. Santoro and {Di Stefano}, D. and E. Ricevuto and M. Maroder and G. Tamburrano and G. Cantore and A. Gulino and S. Martinotti",
year = "1999",
doi = "10.1046/j.1365-2265.1999.00774.x",
language = "English",
volume = "51",
pages = "317--325",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - p16 (INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours

AU - Jaffrain-Rea, Marie Lise

AU - Ferretti, E.

AU - Toniato, E.

AU - Cannita, K.

AU - Santoro, A.

AU - Di Stefano, D.

AU - Ricevuto, E.

AU - Maroder, M.

AU - Tamburrano, G.

AU - Cantore, G.

AU - Gulino, A.

AU - Martinotti, S.

PY - 1999

Y1 - 1999

N2 - OBJECTIVE: The p16 gene, which encodes a physiological inhibitor of the cyclin D-CDK4 complex, is now considered as an important tumour-suppressor gene in a variety of tumours. A marked reduction of its expression has been reported to occur without significant genetic alterations in human pituitary adenomas, although rare point mutations of uncertain functional significance have been described. On the other hand, p16 gene silencing due to hypermethylation has been reported in several human primary tumours. The aim of this study was to further investigate the pathogenetic events leading to p16 gene inactivation in pituitary tumours. DESIGN: To screen a european series of human pituitary tumours for p16 gene alterations and possible gene hypermethylation. PATIENTS: A representative series of 31 human pituitary tumours - 30 macroadenomas, including a MEN-1 non-secreting pituitary adenoma and a non-MEN-1 familial giant GH-secreting adenoma, and one FSH-secreting pituitary carcinoma was studied. METHODS: Polymerase chain reaction/single strand conformation polymorphism (PCR-SSCP) analysis was used to screen for p16 gene alterations in all cases. Direct sequencing of PCR-products was obtained by the di-deoxynucleotide method where suspected abnormalities of the PCR-SSCP analysis were observed. In 24 samples, a methylation-specific PCR assay (MSP-PCR) was used to determine p16 gene methylation status. RESULTS: Two sporadic cases of pituitary adenomas had a similar single A to G base substitution leading to an heterozygous Ala140Thr p16 polymorphism, which has not previously been described in such tumours, but is known to be functionally silent. No other p16 abnormality could be suspected from PCR- SSCP analysis in this series. In contrast, the presence of methylated- specific PCR products was observed in 20/24 cases (83.3%). CONCLUSIONS: This study confirms that p16 gene mutations are not involved in the pathogenesis of human pituitary tumours, although polymorphisms can be demonstrated, depending on the population considered. In contrast, the high incidence of hypermethylation of the p16 gene suggests that such an alteration occurs early in pituitary tumours, and may play a role in pituitary tumorigenesis.

AB - OBJECTIVE: The p16 gene, which encodes a physiological inhibitor of the cyclin D-CDK4 complex, is now considered as an important tumour-suppressor gene in a variety of tumours. A marked reduction of its expression has been reported to occur without significant genetic alterations in human pituitary adenomas, although rare point mutations of uncertain functional significance have been described. On the other hand, p16 gene silencing due to hypermethylation has been reported in several human primary tumours. The aim of this study was to further investigate the pathogenetic events leading to p16 gene inactivation in pituitary tumours. DESIGN: To screen a european series of human pituitary tumours for p16 gene alterations and possible gene hypermethylation. PATIENTS: A representative series of 31 human pituitary tumours - 30 macroadenomas, including a MEN-1 non-secreting pituitary adenoma and a non-MEN-1 familial giant GH-secreting adenoma, and one FSH-secreting pituitary carcinoma was studied. METHODS: Polymerase chain reaction/single strand conformation polymorphism (PCR-SSCP) analysis was used to screen for p16 gene alterations in all cases. Direct sequencing of PCR-products was obtained by the di-deoxynucleotide method where suspected abnormalities of the PCR-SSCP analysis were observed. In 24 samples, a methylation-specific PCR assay (MSP-PCR) was used to determine p16 gene methylation status. RESULTS: Two sporadic cases of pituitary adenomas had a similar single A to G base substitution leading to an heterozygous Ala140Thr p16 polymorphism, which has not previously been described in such tumours, but is known to be functionally silent. No other p16 abnormality could be suspected from PCR- SSCP analysis in this series. In contrast, the presence of methylated- specific PCR products was observed in 20/24 cases (83.3%). CONCLUSIONS: This study confirms that p16 gene mutations are not involved in the pathogenesis of human pituitary tumours, although polymorphisms can be demonstrated, depending on the population considered. In contrast, the high incidence of hypermethylation of the p16 gene suggests that such an alteration occurs early in pituitary tumours, and may play a role in pituitary tumorigenesis.

UR - http://www.scopus.com/inward/record.url?scp=0033183349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033183349&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2265.1999.00774.x

DO - 10.1046/j.1365-2265.1999.00774.x

M3 - Article

VL - 51

SP - 317

EP - 325

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -